ELICIO THERAPEUTICS, INC.

Other languages Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-06-13 EDT			5-day change	1st Jan Change
8.17 ^USD	-3.77%		+4.34%	-2.04%

05-23	Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting	CI
05-15	Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting	05-23
Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15
Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting	04-05
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29
Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	01-25
Elicio Therapeutics Reports First Patient Dosed in Mid-Stage Pancreatic Cancer Trial	01-11
Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study	01-11
Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	01-09
Elicio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer	23-10-12
Elicio Therapeutics Says Solid Tumor Phase 1 Study of ELI-002 Showed 'Promising' Preliminary Relapse-Free Survival Data	23-09-28
Elicio Therapeutics, Inc. Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of Eli-002 At AACR Special Conference: Pancreatic Cancer	23-09-27
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Elicio Therapeutics Reports 'Positive' Results From Phase 1 Cancer Immunotherapy Trial; Shares Jump Premarket	23-06-05
Elicio Therapeutics, Inc. Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer	23-06-03
Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.	23-05-31
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer